WASHINGTON, May 17 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration (FDA) has issued a notice regarding the regulatory review period determination for the human biological product ELAHERE (mirvetuximab soravtansine-gynx), as published in the Federal Register on May 19, 2025. ELAHERE, developed by ImmunoGen, Inc., is indicated for the treatment of adult patients with folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or   more